Immutep
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Industry Lists
Public Companies - non WAImmutep Limited (IMM, Prima BioMed Ltd) is a biotechnology company headquarters in Australia. IMM focuses on personalised bio-therapeutic products for cancer. Its main products are eftilagimod alpha ("Efti" or " IMP321"), a soluble LAG-3Ig fusion protein, which is in clinical development for the treatment of cancer. Immutep has two other clinical candidates (IMP701 and IMP731) that are fully licensed to major pharmaceutical partners, and a fourth candidate (IMP761) which is in pre-clinical development.
Contact Details
Level 12, 95 Pitt St, SYDNEY NSW 2000
02 8315 7003
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 877th |  | Immutep | $4.3m |
| 1025th | | Afterpay | $778k |
| 1026th | | Raptis Group | $778k |
| 1029th | | Fat Prophets Global Contrarian Fund | $732k |
| 1030th | | Ansarada Group | $721k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 192nd | Immutep | 54% | 4% |
| 890th | Fat Prophets Global Contrarian Fund | -11% | 2% |
| 1170th | Afterpay | -30% | -20% |
| 1171st | Raptis Group | -30% | -20% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: F Triebel, CSO & CMO | 24 Nov 2020 |
| REMUNERATION UPDATE: Pete A Meyers, Non-Executive Deputy Chairman, Non-Executive Director | 13 Nov 2020 |
| REMUNERATION UPDATE: Marc Voigt, Chief Executive Officer, Executive Director | 13 Nov 2020 |
| REMUNERATION UPDATE: Grant Chamberlain, Non-Executive Director | 13 Nov 2020 |
| REMUNERATION UPDATE: Deanne Miller, Chief Operating Officer, Company Secretary, General Counsel | 13 Nov 2020 |
| REMUNERATION UPDATE: Russell J Howard, Non-Executive Chairman, Non-Executive Director | 13 Nov 2020 |
| NEW ROLE: Tom RJ Bloomfield, Joint Company Secretary | 03 Nov 2020 |
| NEW ROLE: Deanne Miller, Chief Operating Officer, Company Secretary, General Counsel | 03 Nov 2020 |
| NEW ROLE: Russell J Howard, Non-Executive Chairman, Non-Executive Director | 03 Nov 2020 |
